To this end, although 2‐BP reduced mTORC1/S6K activation in RCC cells (Figure S8T, Supporting Information), treatment with 2‐BP failed to sensitize A498 or 786‐o cells to rapamycin (Figure S9A,B, Supporting Information), temsirolimus (Figure S9C, Supporting Information), everolimus (Figure S9D, Supporting Information) nor S6K1 inhibitor (S6K‐I) (Figure S9E,F, Supporting Information). This evidence concerns the gene RPS6KB1 and renal cell carcinoma.